Menu
Enrolling by invitation NCT07320638

TRIM25 in Septic Patients

Observational Sepsis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Gene and Inflammatory Marker Analysis in Sepsis.
Who it may be relevant to
Registry conditions: Sepsis. Basic parameters: 18 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Expression of Trim25 in Peripheral Blood Mononuclear Cells of Patients With Sepsis and Non-sepsis and Its Relationship With the Prognosis of Patients With Sepsis

Overview

Sepsis is a life-threatening condition caused by the body's overwhelming response to infection, which can lead to organ damage and failure. The goal of this observational study is to better understand the underlying biological changes that occur in patients with sepsis compared to those who do not have the condition. We will collect peripheral blood samples from patients diagnosed with sepsis and from non-sepsis control participants. From these samples, we will isolate peripheral blood mononuclear cells (PBMCs) and serum. We will then analyze these components to measure the activity of specific genes and the levels of key inflammatory factors (cytokines). The information we gather will help researchers identify molecular and inflammatory markers associated with sepsis. This knowledge is crucial for developing new and more effective methods for diagnosing and treating this critical illness.

Interventions

  • Diagnostic test Gene and Inflammatory Marker Analysis in Sepsis
    1.Sepsis Group: 1. SOFA score \>=2; 2. Aged 18-70 years male and female; 3. Hospitalization. 2.Non-sepsis Group: (1) Healthy adults; (2) Aged 18-70 years male and female.

Primary outcome measures

  • TRIM25 in PBMCs [Time frame: From 2021.12 to 2026.06]

Eligibility criteria

Inclusion criteria

  • 1\. SOFA score >=2; 2. Aged 18-70 years male and female; 3. Hospitalization.

Exclusion criteria

  • 1\. Immune system disease, such as HIV; 2. Disease that possibly affect the function of immune system, such as tumor and chronic viral infection; 3. Patients that treated with massive cortical hormone (>200mg/d) or immunosuppressant; 4. Pregnant or lactation women.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Shanghai JiaoTong University School of Medicine — Shanghai

Identifiers

NCT: NCT07320638 · Sepsis-2021-278 · 81900073

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗